Occulus +
Description
Complementary feed that provides nutrients to the lens.
Lutein and Zeaxanthin: Help to protect the lens by decreasing the progression of opacities (nuclear cataracts) in humans (1). In in vitro studies, they protect against oxidative damage (2).
Minerals (Zn, Cu): Essential for eye development; help slow visual acuity loss in humans (8, 9, 10).
Vitamins (A, C, E): They have been seen that help to prevent nuclear and cortical cataracts in humans, reducing the risk of cataract development (6,7). Invitro studies show antioxidant action (1).
Vitamins (D3, K): Related to the metabolism of insulin and glucose (6). They have been linked to reducing the progression of cataracts in humans (6,7).
Vitamin D shows anti-inflammatory action (5).
Minerals (Ca): Helpful in cataracts that occur due to hypocalcemia (8); helps slow down the progression of lens opacities in humans (5).
Vitamins (B1, B2, B3, B6, B7, B9, B12): Important for the activation of some antioxidants and the depletion of homocysteine, helping
to slow the cataract onset in humans (1,9,10,11).
Alpha lipoic acid: Antioxidant effect (12). Helps to protect retinal ganglion cells in diabetic retinopathies (13).
Aldose Reductase Inhibitor (sorbitol generator) (14,15). Slows down the progression of diabetic cataract in dogs (16).
COMPOSITION
COMPOSITION PER TABLET (750mgr): Tricalcium phosphate; Calcium hydrogen orthophosphate; Magnesium tribasic citrate; Calendula
officinalis; Wheat starch; Alpha lipoic acid (15mg); Magnesium stearate; Marigold flower (Tagetes erecta) (Lutein, 4mg and Zeaxanthin 0.5mg); Copper.
ADDITIVES PER TABLET (750mgr):
Flavouring agents: Chicken flavouring.
Vitamins: Calcium D-pantothenate, Vitamin B6, Biotin,Vitamin A, Vitamin D3, Folic Acid, Vitamin B12, Niacinamide, Vitamin K3,
Vitamin B1, Vitamin B2, Vitamin C, Vitamin E.
Oligoelements: Iodine (potassium iodide) (0.046mg); Selenium (Sodium Selenite) (0.014mg); Manganese (Manganous sulfate monohydrate) (0.943mg);
Zinc (Zinc sulfate, monohydrate)(2.8mg).
INSTRUCTIONS FOR USE
Oral administration, once daily, with one of the main meals.
Pets under 5kg: ½ tablet
Pets from 5 to 10kg: 1 tablet
Pets from 10 to 20kg: 1½ tablets
Pets from 20 to 40kg: 2 tablets
Pets over 40kg: 2½ tablets
STORAGE CONDITIONS
Store in a cool and dry place, protected from light.
PRESENTATION
Solid form: 30 tablets.
References
(1) Zhao, L.-Q., Li, L.-M., Zhu, H. & Evidence-Based Eye Disease Study Research Group, T. E. The Effect of
Multivitamin/Mineral Supplements on Age-Related Cataracts: A Systematic Review and Meta-Analysis. Nutrients 6,
931–949 (2014).
(2) Gao, S. et al. Lutein and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens
epithelial cells. Mol Vis 17, 3180–90 (2011).
(3) Grahn, B. H., Paterson, P. G., Gottschall-Pass, K. T. & Zhang, Z. Zinc and the eye. Journal of the American
College of Nutrition vol. 20 106–118 Preprint at https://doi.org/10.1080/07315724.2001.10719022 (2001).
(4) Barman, S. & Srinivasan, K. Zinc Supplementation Ameliorates Diabetic Cataract Through Modulation of
Crystallin Proteins and Polyol Pathway in Experimental Rats. Biol Trace Elem Res 187, 212–223 (2019).
(5) Atalay, K. Serum Vitamin D Levels in Different Morphologic Forms of Age Related Cataract. Acta
Endocrinologica (Bucharest) 16, 178–182 (2020).
(6) Camacho-Barcia, M. L. et al. Association of dietary Vitamin K1 intake with the incidence of cataract surgery in
an adult mediterranean population a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 135,
657–661 (2017).
(7) Öktem, C. & Aslan, F. Vitamin D Levels in Young Adult Cataract Patients: A Case-Control Study. Ophthalmic
Res 64, 116–120 (2021).
(8) Freedman, D. B., Smith, N. & Abstract, D. H. Case Report Profound hypocalcaemia associated with bilateral cataracts
post-total thyroidectomy. http://www.acb.org.uk/docs/TFTguidelinefinal.pdf.
(9) Glaser, T. S. et al. The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with Cataracts in the Age-Related Eye
Disease Study AREDS Report No. 37. Ophthalmology 122, 1471–1479 (2015).
(10) Sperduto, R. D. et al. The Linxian cataract studies. Two nutrition intervention trials. Arch Ophthalmol 111, 1246–53 (1993).
(11) Vinson, J. A. Oxidative stress in cataracts. Pathophysiology 13, 151–62 (2006).
(12) Busse, E., Zimmer, G., Schopohl, B. & Kornhuber, B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and
in vivo. Arzneimittelforschung 42, 829–31 (1992).
(13) Kan, E., Alici, Ö., Kan, E. K. & Ayar, A. Effects of alpha-lipoic acid on retinal ganglion cells, retinal thicknesses, and VEGF
production in an experimental model of diabetes. Int Ophthalmol 37, 1269–1278 (2017).
(14) Hejtmancik, J. F. et al. Lens Biology and Biochemistry. in Progress in Molecular Biology and Translational Science vol. 134
169–201 (Elsevier B.V., 2015).
(15) Reljanovic, M. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid ( α -lipoic acid): A two year
multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 31, 171–179 (1999).
(16) Williams, D. L. Effect of oral alpha lipoic acid in preventing the genesis of canine diabetic cataract: A preliminary study.
Vet Sci 4, (2017).